deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04899271

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes and Preserved Beta-cell Function at Baseline.

Sponsor: Dompé Farmaceutici S.p.A

Conditions New-onset Type 1 Diabetes
Interventions Ladarixin Placebo
Updated 15 times since 2021 Last updated: May 13, 2025 Started: Dec 14, 2020 Primary completion: Apr 27, 2023 Completion: Oct 11, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

low recruitment rate

Other terminated trials from Dompé Farmaceutici S.p.A

More terminations from Dompé Farmaceutici S.p.A

A PHASE2 clinical study on New-onset Type 1 Diabetes, this trial is terminated or withdrawn. The trial is conducted by Dompé Farmaceutici S.p.A and has accumulated 15 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jun 2023 · 12 months · monthly snapshot~Jun 2023 – ~Nov 2023 · 5 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Jun 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Jan 2024 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 10 earlier versions

  1. Dec 2023 — Jan 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2022 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  6. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  7. Nov 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  8. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  9. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  10. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dompé Farmaceutici S.p.A
Data source: Dompé Farmaceutici S.p.A

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Bari, Italy , Belgrade, Serbia , Catanzaro, Italy , Glessen, Germany , Heidelberg, Germany , Jette, Belgium , Kragujevac, Serbia , Milan, Italy and 5 more locations